

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701

TELEPHONE: 512/474-5201
FACSIMILE: 512/536-4598

STEVEN L. HIGHLANDER
PARTNER

INTERNET ADDRESS
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL 512/536-3184


HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG



**COPY OF PAPERS
ORIGINALLY FILED**

March 11, 2002

FILE: UTSB:679USD1
10107746

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
<u>March 11, 2002</u> Date	 Steven L. Highlander

Commissioner for Patents
Washington, DC 20231

RE: *SN 09/940,173 "INHIBITION OF HUMAN TELOMERASE BY AS G-QUADRUPLEX-INTERACTION COMPOUND – By Sean M. Kerwin et al.*

Commissioner:

Enclosed for filing in the above-referenced patent application is:

1. Notice to File Corrected Application Papers;
2. Response to Notice to File Corrected Application Papers;
3. Figures 1-8 on 11 Sheets;
4. Paper Copy of Sequence Listing; Computer Readable Form (CRF);
5. Request for an Extension of Time of one month to and including March 11, 2002;
6. A check for \$55.00 as the fee for the extension of one-month time; and
7. A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

If the check is inadvertently omitted, or the amount is insufficient, or should any additional fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, or


Commissioner for Patents

March 11, 2002

Page 2

should an overpayment be included herein, the Commissioner is authorized to deduct or credit said fees from or to Fulbright & Jaworski L.L.P. Account No.: 50-1212/10107746/SLH.

Respectfully submitted,

A handwritten signature in black ink, appearing to be "SLH", is written over a circular stamp. The signature is fluid and cursive.

Steven L. Highlander
Reg. No. 37,642

SLH/cpj

Encl.:



COPY OF PAPERS
ORIGINALLY FILED

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
March 11, 2002 Date	Steven L. Highlander

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Sean M. Kerwin et al.

Group Art Unit: Unknown

Serial No.: 09/940,173

Examiner: Unknown

Filed: August 27, 2001

Atty. Dkt. No.: UTSB:679USD2/SLH

For: INHIBITION OF HUMAN TELOMERASE
BY AS G-QUADRUPLEX-
INTERACTION COMPOUND

RESPONSE TO NOTICE TO FILE CORRECTED APPLICATION PAPERS

Commissioner for Patents
Washington, D.C. 20231

Commissioner:


This paper is submitted in response to the Notice to File Corrected Application Papers dated December 10, 2001 for which the two-month date for response was February 10, 2002.

A request for a one-month extension of time to respond is included herewith along with the required fee. This one-month extension will bring the due date to March 11, 2002, which is within the six-month statutory period. Should such request or fee be deficient or absent, consider this paragraph such a request and authorization to withdraw the appropriate fee under 37 C.F.R. §§ 1.16 to 1.21 from Fulbright & Jaworski L.L.P. Account No.: 50-1212/10107746/SLH.

RESPONSE TO NOTICE

Submitted herewith are figures 1-8 on 11 sheets; paper copy of sequence listing and computer readable form (CRF) of sequence listing in compliance with 37 CFR 1.52 as requested. Applicants believe that the attached documents fully respond to the Notice to File Corrected Application Papers for this application.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 536-3184
(512) 536-4598 (facsimile)

Date: March 11, 2002



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/940,173	08/27/2001	Sean M. Kerwin	UTSB:679USD2

CONFIRMATION NO. 5375

FORMALITIES LETTER



OC000000007176714

Steven L. Highlander, Esq.
FULBRIGHT & JAWORSKI L.L.P.
Suite 2400
600 Congress Avenue
Austin, TX 78701

COPY OF PAPERS
ORIGINALLY FILED

Date Mailed: 12/10/2001

NOTICE TO FILE CORRECTED APPLICATION PAPERS

Filing Date Granted

This application has been accorded an Application Number and Filing Date. The application, however, is informal since it does not comply with the regulations for the reason(s) indicated below. Applicant is given **TWO MONTHS** from the date of this Notice within which to correct the informalities indicated below. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a)

The required item(s) identified below must be timely submitted to avoid abandonment:

- Substitute drawings in compliance with 37 CFR 1.84 because:
 - drawing sheets do not have the appropriate margin(s) (see 37 CFR 1.84(g)). Each sheet must include a top margin of at least 2.5 cm. (1 inch), a left side margin of at least 2.5 cm. (1 inch), a right side margin of at least 1.5 cm. (5/8 inch), and a bottom margin of at least 1.0 cm. (3/8 inch);
- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c) Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A request to transfer the computer readable form from another application on file at the U.S. Patent and Trademark Office has been submitted as permitted by 37 C.F.R. 1.821(e). However, the request cannot be complied with since there is no compliant CRF present at the United States Patent and Trademark Office. Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE